Darzalex IV savings card: as little as $5 a dose with commercial insurance

Darzalex IV is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Darzalex IV is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameDarzalex IV

Authorized genericdaratumumab

Regular genericdaratumumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Darzalex IV?

The original

–

Brand nameThe maker’s card

J&J withMe Savings Program

Savings card from Johnson & Johnson

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $5 a dose

Or call 1-833-565-9631.

In the maker’s words

“Eligible patients pay $5 for each dose.”

From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Darzalex IV itself, from the same company, sold without the brand name, and usually for less. For now Darzalex IV is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Darzalex IV is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Multiple myeloma

What the FDA label says

DARZALEX is a CD38-directed cytolytic antibody indicated for the treatment of adult patients with multiple myeloma:

in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

Source: the FDA label for Darzalex IV (Janssen Biotech, Inc.), September 21, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/darzalex-iv/